Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
In October-November 2026, vendors across the stack turned AI into operational products. Fortinet, Cisco and T-Mobile focused on securing AI and the network, Encord and Harvest Praxis/MediaTek on physical-AI data and chips, and NVIDIA RTX Spark laptops and the new iPad mini on edge hardware. Salesforce's Braze acquisition shows consolidation toward AI-driven customer engagement, while small-cap TEN Holdings restructures toward SaaS. Executives are broadly upbeat but frame the bottleneck as data, security and integration cost rather than model capability.
The 2026 ESMO Congress drove a cluster of late-October oncology data releases and launches: Summit's ivonescimab, Incyte's pancreatic cancer (PDAC) pipeline, Astellas' CLDN18.2 real-world evidence, AstraZeneca's ZEGFROVY US launch and Abbott's whole-genome sequencing (WGS) MRD test. At the same time, smaller or struggling players are retrenching through a Nasdaq First North delisting, a SPAC LOI, and ADC Therapeutics' workforce cuts to extend its cash runway into 2028. The picture is a strong clinical and commercial pipeline for well-capitalized leaders and cost-cutting or exits for the rest, with little visible financing optimism for the small end of the market.
A sharp mid-October to early-November 2026 semiconductor and AI/data-center selloff (SOX's longest losing streak since 2008, its worst session since March 2020, and the S&P 500's worst day since April 2025) pushed the VIX higher. It hit amid midterm-election uncertainty, mixed earnings guidance (Trimble's 2027 headwind) and growing concern over unprecedented AI capex and legal and regulatory pressure. Underneath, AI adoption keeps broadening into healthcare, defense, education and enterprise software, the Anthropic IPO is expected to be a market bellwether, and bull-case valuations (Alphabet's $427.89 fair value) rest on converting AI engagement into earnings. Fraud cases like Joonko, where the founder pleaded guilty to securities fraud, add a note of investor-protection caution.
On Nov 5, 2026 the Nasdaq had its worst day since April 2025. The Magnificent Seven lost over $1 trillion, and Tesla and SpaceX lost over $420 billion combined. The next day Democrats signaled plans to rein in Big Tech, and Tesla said it would wind down Cybertruck production. Over the same period, financial-services firms such as East West Bancorp, FNF, LY Corp (PayPay/fintech) and Canara HSBC Life reported solid earnings, raised guidance and increased dividends. JPMorgan's selective aerospace and defense ratings point to investors rotating toward earnings-backed names, while AI-investor enthusiasm (IEQ Capital's party, Viola FinTech's 40 NYC AI portfolio companies) and enterprise AI adoption (Lenovo edge computer vision at a European retail bank) continue.
The Q3 2026 reporting window is dominated by large capital events: OpenAI's round closing at about $1.25T, Fox's DOJ-cleared Roku deal, and Shield AI's purchase of Echodyne. Executives in credit (Robert Stanley's BDC commentary on stable spreads, a favorable rate path, and M&A expected to pick up in Q1–Q2 2027 after the election), fintech and prediction markets (DraftKings' customer-acquisition spend), and small-cap SaaS (TEN Holdings' cost cuts and 17.9% revenue growth) describe a selectively healthy environment. Scheduled CEO transitions (Davis, Hogan) and year-end regulatory and rate changes (Alberta auto reform, Florida City Gas) add continuity and policy risk. Biotech data readouts such as Arrowhead's are present but peripheral to the AI-finance theme.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedArgan outlines $2.9B backlog strength and signals continued demand for large power projects
“Argan outlines $2.9B backlog strength and signals continued demand for large power projects Earnings Call Insights: Argan, Inc…”
QCI CTO Andrew Cardno to Take the Stage for Key Sessions on Security Innovation and Player Engagement at IGA 2026
“QCI CTO Andrew Cardno to Take the Stage for Key Sessions on Security Innovation and Player Engagement at IGA 2026 SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI) Co-Founder and Chief Technology Officer Andrew Cardno will take the stage at the Indian Gaming Association Tradeshow & Conventio…”
Trump sues ‘woke’ JP Morgan for $5bn over debanking
“Trump sues ‘woke’ JP Morgan for $5bn over debanking Donald Trump is suing JP Morgan and its chief executive, Jamie Dimon. - Krisztian Bocsi/Bloomberg Donald Trump is suing JP Morgan and its chief executive Jamie Dimon for $5bn (£3.7bn) over claims it debanked him…”
Can quantum computers now solve health care problems? We’ll soon find out.
“MIT Technology Review - Ai Research Title: Can quantum computers now solve health care problems? We’ll soon find out…”
Stocks Surge on Signs the US and Iran Seek to End War
“Stocks Surge on Signs the US and Iran Seek to End War The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +2.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.43%…”
We All Know We Should Have An Emergency Fund. But One Homeowner Cautions Not To Name It 'House Emergency Fund.' Here's Why
“We All Know We Should Have An Emergency Fund. But One Homeowner Cautions Not To Name It 'House Emergency Fund.' Here's Why Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Nasdaq expects a 23-hour trading day from 6 December 2026, pending regulatory approval. Robinhood's SEC-filed revenue has grown about 2.4 times since 2023. Meanwhile an AI-identity startup says unverified agents 'will just get blocked everywhere'. We separate the checked figures from the claims.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3 while crypto fell 55%, and Nasdaq and the CFTC are weighing near-24-hour markets. We checked each figure against SEC filings and graded the sources. Several key claims come from sources with mixed track records.
Checked SEC filings show Micron's capital spending nearly doubled in a year and its cash reached $25.0 billion. Record results at smaller suppliers add to the picture. We also flag where the sources disagree and which have a weak track record.
Funding is concentrating on proving who an AI agent is and who it acts for, while incumbents buy and brokers launch new products. SEC-filed figures show Robinhood's revenue rose from $1.865 billion to $4.473 billion in two years. One investor warns AI should not do finance maths.
In its latest quarter Robinhood reported event-contract revenue of $173M, up more than sixfold, while crypto revenue fell 55%. Nasdaq, Cboe and the CFTC are all pushing toward longer trading hours. Every figure here is traced to SEC filings or named documents, and we flag where sources are weaker.
Vor Bio reported two-year Phase 3 kidney results, Incyte's SEC-filed profit rose from $32.6 million to $1.29 billion in a year, and BioArctic's Leqembi royalty grew. Much of the early-stage news rests on company statements. We separate checked figures from claims.
Third-quarter reports split into two stories: a chip-equipment maker guiding to $8.6 billion of quarterly revenue on AI spending, and chemical and rail CFOs trimming costs against fuel and energy. We checked Dow's figures against SEC filings and flag where the evidence is thin.
Third-quarter calls from Lam Research, Dow and Union Pacific show two economies. AI-linked chip demand is outrunning supply, while chemicals and rail protect profit through cost cuts. Every figure is traced to a named speaker, an SEC filing or a source document.
Web Summit Lisbon's edition returns from 9 to 12 November, and the organisers' featured speakers page has a detail still rare at tech conferences: two of the "speakers" are robots.
Dow says its cost-cutting is ahead of schedule while its latest full-year results show the hole it is climbing out of. Union Pacific posted record profit and wants a merger. Both claims come from earnings calls, and the source's measured accuracy is 60%, so we separate what SEC filings confirm from what executives said.
Q3 2026 earnings calls show finance chiefs relying on cost cuts and cash cushions while energy costs stay high. Dow targets $1.3 billion of net benefits and Union Pacific's fuel price rose 64%. The figures come from earnings-call transcripts and SEC-checked filings; we flag where reporting is less certain.
Robinhood's checked SEC figures show revenue up about 2.4 times in two years and a swing from loss to profit. Now it is the first retail broker to offer Cboe's company-performance contracts, while startups raise money to prove AI agents can be trusted. Some of the evidence is thin, and we say where.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
The FDA approved a twelfth Tecentriq use, and a decision on Summit's ivonescimab is due Nov 14. Summit's SEC-filed accounts show losses and cash burn rising sharply. AstraZeneca's AI vision is, by its own telling, a forecast and not yet a result.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
Cancer drug makers are betting on newer treatment types, and regulators have started to approve some. Summit Therapeutics' filings show how costly that bet is: a $1.08 billion net loss in 2025 with zero revenue. The FDA rules on its lead drug on Nov. 14. The AI claims behind the story are forecasts, not results.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.